ORIC Q1 cash $224M; extends runway to 2027; plans Phase 3 for 2 programs in 2026

Oric Pharmaceuticals, Inc.

2025-Q1 EPS reported -$0.42

Cash and investments $223.8M at March 31, 2025; expected to fund operations into 2027 (vs previous guidance of late 2026).
R&D expenses $24.6M for Q1 2025, up from $22.0M YoY due to pipeline advancement and higher personnel costs.
Registrational plan for ORIC-944 in mCRPC: first Phase 3 trial targeted for 1H 2026; ORIC-114 Phase 3 in 1L NSCLC expected later in 2026.
Entered clinical trial collaboration with Johnson & Johnson for ORIC-114 plus subcutaneous amivantamab in 1L EGFR exon 20 NSCLC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.